Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the
family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new …

Immune checkpoint inhibitors have revolutionized cancer therapy by blocking inhibitory
pathways of the immune system to fight cancer cells. Their use is often limited by the …

Immune checkpoint inhibitors have advanced the treatment paradigm of various cancers,
achieving remarkable survival benefits. However, a myriad of immune-related adverse …

Background The use of immune checkpoint inhibition (ICI) has revolutionized cancer
treatment. However, these medications are associated with significant and potentially …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …

Immunotherapy of cancer with checkpoint inhibitors has been associated with a spectrum of
autoimmune and systemic inflammatory reactions known as immune-related adverse events …

Objectives To evaluate the prevalence and type of rheumatic immune-related adverse
events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the …

Compared with conventional cancer therapies, the spectrum of toxicities observed with
checkpoint inhibitors is unique and can affect any organ system. Arthralgia and myalgia …

Objective Immune checkpoint inhibitors (ICI s) are improving prognoses in advanced stage
cancers, but they also lead to immune‐related adverse events (IRAE s). IRAE s targeting …

Objective Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy,
their use is associated with immune toxicities referred to as immune-related adverse events …